Development of N -(4-(1 H -Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability
Journal of Medicinal Chemistry · 28.11.2024 · 67 (22) · 20298-20314
DOI: 10.1021/acs.jmedchem.4c01708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.11.2024. Verfasst von Michela Puxeddu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of R…. Hauptthemen laut MEDLINE: Antineoplastic Agents, beta Catenin, Sulfonamides, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Ministero dell?Istruzione, dell?Universit? e della Ricerca, Sapienza Universit? di Roma, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
The potential as a cancer therapeutic target of the recently reported hotspot binding region close to Lys508 of the β-catenin armadillo repeat domain was not exhaustively explored. In order to get more insight, we synthesized novel N-(heterocyclylphenyl)benzenesulfonamides 6-28. The new compounds significantly inhibited Wnt-dependent transcription as well as SW480 and HCT116 cancer cell proliferation. Compound 25 showed binding mode consistent with this hotspot binding region. Compound 25 inhibited the growth of SW480 and HCT116 cancer cells with IC50's of 2 and 0.12 μM, respectively, and was superior to the reference compounds 5 and 5-FU. 25 inhibited the growth of HCT-116 xenografted in BALB/Cnu/nu mice, reduced the expression of the proliferation marker Ki67, and significantly affected the expression of cancer-related genes. After incubation with human and mouse liver microsomes, 25 showed a higher metabolic stability than 5. Compound 25 aims to be a promising lead for the development of colorectal cancer anticancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
- Department of Acupuncture and Moxibustion, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, 200086 Shanghai, China.
- Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161 Rome, Italy.
- Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.
- Department of Organic Chemistry, University of Chemistry and Technology Prague, Technická 5, 16628 Prague 6, Czech Republic.
- GSTeP-Organoids Research Core Facility, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.
ORCID-Profile: Michela Puxeddu, Antonio Coluccia, Domiziana Masci, Petra Cuřínová, Mariano Stornaiuolo, Giulio Dondio, Romano Silvestri, Giuseppe La Regina
Förderung
- Ministero dell?Istruzione, dell?Universit? e della Ricerca
- Sapienza Universit? di Roma
- Associazione Italiana per la Ricerca sul Cancro
- China Academy of Traditional Chinese Medicine
- Ministero della Salute
- Ministero dell'Universit? e della Ricerca
- Universit? Cattolica del Sacro Cuore
- Fondazione Umberto Veronesi
Zitieren
APA
Puxeddu, M., Ling, L., Ripa, S., D'Ambrosio, M., Nalli, M., Parisi, A., Sciò, P., Coluccia, A., Granese, A., Santelli, M., Masci, D., Cuřínová, P., Naro, C., Sette, C., Pastore, A., Stornaiuolo, M., Bigogno, C., Dondio, G., Di Magno, L., …, & La Regina, G. (2024). Development of N -(4-(1 H -Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability. Journal of Medicinal Chemistry, 67(22), 20298-20314. https://doi.org/10.1021/acs.jmedchem.4c01708
Vancouver
Puxeddu M, Ling L, Ripa S, D'Ambrosio M, Nalli M, Parisi A, et al. Development of N -(4-(1 H -Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability. Journal of Medicinal Chemistry. 2024;67(22):20298-20314. doi:10.1021/acs.jmedchem.4c01708
BibTeX
@article{Puxeddu2024,
author = {Puxeddu, Michela and Ling, Lele and Ripa, Silvia and D'Ambrosio, Michele and Nalli, Marianna and Parisi, Anastasia and Sciò, Pietro and Coluccia, Antonio and Granese, Arianna and Santelli, Martina and Masci, Domiziana and Cuřínová, Petra and Naro, Chiara and Sette, Claudio and Pastore, Arianna and Stornaiuolo, Mariano and Bigogno, Chiara and Dondio, Giulio and Di Magno, Laura and Canettieri, Gianluca and Liu, Te and Silvestri, Romano and La Regina, Giuseppe},
title = {Development of N -(4-(1 H -Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {22},
pages = {20298--20314},
doi = {10.1021/acs.jmedchem.4c01708}
}
EUVIMED